The value of cell and gene therapies to the UK economy

Chris Sampson, Sukanya Subramaniyan, Matthew Napier, Hania El Banhawi, Panos Kefalas, Laura Beswick, Jacqueline Barry, Matthew Durdy and Grace Hampson

Contract Research from Office of Health Economics

Abstract: Cell and gene therapies (CGTs) are moving rapidly from specialist trials to routine care: more than thirty products are already licensed worldwide and over two thousand are in clinical development.

JEL-codes: I1 (search for similar items in EconPapers)
Date: 2025-10-20
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/value-of-cell-and ... s-to-the-uk-economy/ (text/html)
https://www.ohe.org/wp-content/uploads/2025/10/Sam ... UK-economy-FINAL.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:conres:002513

Access Statistics for this paper

More papers in Contract Research from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).